Turn this list into an evaluation

Each entry is an FDA submission, not a distinct commercial offer. Inspect the exact record before comparing evidence, asking for a quote or planning an integration.

Prepare with a buyer guide:

Clinical guide links appear when this list contains a current reviewed example. They do not classify or endorse the other entries. All buyer guides · Compare exact records · Documented families

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K254131

BAC

DeepHealth, Inc.

Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2026-05-21
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K252482

CogNet AI-MT+

Medcognetics, Inc.

Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-12-11
FDA-approved P130020/S005

Senographe Pristina 3D

GE Healthcare

PMA supplement updates digital breast tomosynthesis reconstruction with deep learning to correct sparse-view artifacts, compensate patient motion, and enhance soft-tissue lesion visibility in the synthetic 2D image.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-11-21
FDA-cleared K243685

MammoScreen BD

Therapixel

Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-08-22
FDA-cleared K251873

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Saige-Dx analyzes screening DBT stacks and associated full-field digital or synthetic 2D mammograms, assigning finding and case suspicion levels to support qualified interpreting physicians; it does not replace their review or clinical judgment.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-08-11
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31
FDA-cleared K243679

MammoScreen® (4)

Therapixel

Authorized purpose: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-03
FDA-authorized DEN240047

Allix5

Clairity, Inc.

Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-05-30
FDA-cleared K250754

cmAngio® (V1.6)

CureMetrix, Inc.

Authorized purpose: cmAngio (V1.6) processes screening mammograms to aid a qualified interpreting physician in the manual process of identifying breast arterial calcification. It detects the presence or absence of breast arterial calcifications at the study and breast level in full-field digital mammography and digital breast tomosynthesis screening mammograms and marks BAC segments on image thumbnails for localization.

Modality
Mammography/DBT
Anatomy
Female breasts; breast arterial calcification
Decision
2025-04-10
FDA-cleared K243688

Saige-Dx (3.1.0)

DeepHealth, Inc.

Authorized purpose: Concurrent reading aid for qualified interpreting physicians on screening DBT mammograms to identify soft-tissue lesions and calcifications that may indicate cancer and assign finding- and case-level suspicion.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-12-19
FDA-cleared K243705

Saige-Density (2.5.0)

DeepHealth, Inc

Authorized purpose: Adjunctive assignment of a BI-RADS 5th Edition breast-density category for interpreting-physician review of mammography.

Modality
Mammography/DBT
Anatomy
Breast tissue composition
Decision
2024-12-19
FDA-cleared K241831

Transpara (2.1.0)

ScreenPoint Medical B.V.

Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.

Modality
Mammography/DBT
Anatomy
Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
Decision
2024-11-25
FDA-cleared K241747

Saige-Dx

DeepHealth, Inc

Authorized purpose: Concurrent reading aid for interpreting physicians on screening DBT mammograms to detect and characterize soft-tissue lesions and calcifications that may indicate cancer.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-11-18
FDA-cleared K240417

ProFound Detection (V4.0)

iCAD, Inc.

Authorized purpose: Concurrent CAD/CADx aid for interpreting physicians reading compatible DBT exams to detect soft-tissue densities and calcifications for physician confirmation or dismissal.

Modality
Mammography/DBT
Anatomy
Breast.
Decision
2024-11-08
FDA-cleared K242652

Lunit INSIGHT DBT v1.1

Lunit Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-10-04
FDA-cleared K241561

MammoScreen BD

Therapixel

Authorized purpose: Adjunctively assess breast tissue composition and provide an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening mammography; it is not diagnostic.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-10-02
FDA-approved P140011/S008

MAMMOMAT B.brilliant with Tomosynthesis Option

SIEMENS MEDICAL SOLUTIONS USA, INC.

The FDA PMA supplement record identifies MAMMOMAT B.brilliant with Tomosynthesis Option as digital breast tomosynthesis and approves a new PREMIA reconstruction algorithm, updated image-acquisition hardware enabling a faster tomosynthesis scan, and rebranding of the system. The FDA product-classification text states that the device generates digital three-dimensional mammographic images for breast-cancer screening and diagnosis.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-09-23
FDA-cleared K240301

MammoScreen® (3)

Therapixel

Authorized purpose: Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-08-01
FDA-cleared K233108

VinDr-Mammo

VinBigData Joint Stock Company

The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-05-23
FDA-cleared K232096

Transpara Density 1.0.0

Screenpoint Medical B.V.

Authorized purpose: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2023-12-11
FDA-cleared K231470

Lunit INSIGHT DBT

Lunit Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize suspected breast-cancer lesions in screening DBT exams from compatible systems.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2023-11-06
FDA-cleared K232367

cmAngio® V1.0

CureMetrix, Inc.

Authorized purpose: cmAngio processes screening FFDM and DBT mammograms to detect presence or absence of breast arterial calcifications at study and breast level and mark segments for qualified interpreting-physician review; it is not primary breast-cancer interpretation or a standalone diagnostic or treatment decision tool.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2023-10-05
FDA-cleared K223501

ViewFinder Software Version 1.1

Elaitra Ltd

Authorized purpose: Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2023-04-21
FDA-cleared K222275

Saige-Density

DeepHealth, Inc.

Authorized purpose: Provides an adjunctive BI-RADS 5th Edition breast-density category to aid assessment of breast tissue composition; it is not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2022-12-16
FDA-cleared K221449

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.

Modality
Mammography/DBT
Anatomy
Breast; soft-tissue densities, architectural distortions or asymmetries, and calcifications
Decision
2022-10-06
FDA-cleared K220080

CogNet QmTRIAGE

MedCognetics, Inc.

Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2022-09-29
FDA-cleared K221347

Transpara 1.7.2

ScreenPoint Medical B.V.

Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM/DBT to identify suspicious breast regions and estimate malignancy likelihood.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2022-08-03
FDA-cleared K220105

Saige-Dx

DeepHealth, Inc.

Concurrent-reading software for screening DBT mammography that highlights suspected soft-tissue lesions and calcifications for physician review.

Modality
Mammography/DBT
Anatomy
Breast; screening DBT findings and calcifications
Decision
2022-05-12
FDA-cleared K210670

BU-CAD

TaiHao Medical Inc.

Authorized purpose: Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.

Modality
Mammography/DBT
Anatomy
Breast and suspicious soft-tissue breast lesions.
Decision
2021-12-21
FDA-cleared K211541

MammoScreen 2.0

Therapixel

Authorized purpose: Concurrent reading aid for interpreting physicians reading screening FFDM or DBT, to identify findings and assess suspicion; it is not the sole basis for management.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-11-26
FDA-cleared K211678

Lunit INSIGHT MMG

Lunit Inc.

Authorized purpose: Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.

Modality
Mammography/DBT
Anatomy
Breast.
Decision
2021-11-17
FDA-cleared K203785

ClariSIGMAM

ClariPi Inc.

Authorized purpose: Calculation of percent breast density and breast-density group information (BI-RADS A+B fatty versus C+D dense) as adjunctive information for interpreting physicians assessing breast tissue composition; not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast tissue, including fibroglandular tissue and total breast area, assessed for each breast.
Decision
2021-09-10
FDA-cleared K211431

breastscape v1.0

Olea Medical

Authorized purpose: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.

Modality
Mammography/DBT
Anatomy
Breast lesions and breast morphological landmarks including nipple, chest, and skin borders.
Decision
2021-08-02
FDA-cleared K211279

Volpara Imaging Software

Volpara Health Technologies Limited

Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-07-27
FDA-cleared K211506

PowerLook Density Assessment V4.0

iCAD, Inc.

Authorized purpose: Provide a breast-density category from synthetic 2D images generated from DBT to aid assessment of breast tissue composition; the output is adjunctive and not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-07-12
FDA-cleared K210404

Transpara 1.7.0

ScreenPoint Medical B.V.

Authorized purpose: Concurrent reading aid for physicians interpreting screening FFDM and DBT to identify suspicious regions and assess malignancy likelihood.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-06-02
FDA-cleared K203517

Saige-Q

DeepHealth, Inc.

Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-04-16
FDA-cleared K203822

ProFound AI Software V3.0

iCAD Inc.

Authorized purpose: Concurrent or secondary CAD assistance to interpreting physicians for detection, localization, and characterization of soft-tissue densities (masses, architectural distortions, and asymmetries) and calcifications; not a primary read.

Modality
Mammography/DBT
Anatomy
Breast, including soft-tissue densities and calcifications in 3D DBT slices.
Decision
2021-03-12
FDA-cleared K201411

Visage Breast Density

Visage Imaging GmbH

Authorized purpose: Assesses breast density from compatible full-field digital mammography and DBT studies.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-01-29
FDA-cleared K201019

Genius AI Detection

Hologic, Inc.

Authorized purpose: Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.

Modality
Mammography/DBT
Anatomy
Breast; soft-tissue densities and calcifications in digital breast tomosynthesis
Decision
2020-11-18
FDA-cleared K202013

WRDensity by Whiterabbit.ai

Whiterabbit.ai Inc.

Authorized purpose: Analyzes for-presentation digital breast X-ray data to provide breast-density information.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-10-30
FDA-cleared K200905

HealthMammo

Zebra Medical Vision Ltd.

Authorized purpose: Provides passive prioritization-only parallel workflow for suspicious findings in 2D FFDM screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-07-16
FDA-cleared K192854

MammoScreen

Therapixel

Authorized purpose: MammoScreen is a concurrent reading aid for interpreting physicians reviewing screening full-field digital mammography; it marks suspicious soft-tissue lesions and calcifications and provides suspicion scores, while patient management is not based solely on the device.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-03-25
FDA-cleared K193229

Transpara

ScreenPoint Medical B.V.

Authorized purpose: Transpara version 1.6 is a concurrent screening aid for FFDM and DBT that presents suspicious-region marks, region scores from 0 to 100, and an exam score from 1 to 10 for physician review.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-03-05
FDA-cleared K192973

densitas densityai

Densitas, Inc.

Authorized purpose: Provides an ACR BI-RADS 5th Edition breast-density category from compatible full-field digital mammography and DBT as adjunctive information, not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2020-02-19
FDA-cleared K192287

Transpara

Screenpoint Medical B.V.

Authorized purpose: Transpara version 1.5 is a concurrent screening full-field digital mammography aid that presents suspicious-region marks and scores for physician review and cannot be used as the sole basis for interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2019-12-10
FDA-cleared K190442

Koios DS for Breast

Koios Medical, Inc.

Authorized purpose: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.

Modality
Mammography/DBT
Anatomy
Soft-tissue breast lesions.
Decision
2019-07-03
FDA-cleared K183285

cmTriage

CureMetrix, Inc

Authorized purpose: Passive, prioritization-only notification of 2D FFDM screening mammograms with at least one suspicious finding at the exam level; not diagnostic.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2019-03-08
FDA-cleared K181704

Transpara

ScreenPoint Medical BV

Authorized purpose: Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2018-11-21
FDA-cleared K182310

Volpara Imaging Software

Volpara Health Technologies Limited

Authorized purpose: Volpara Imaging Software processes raw digital breast X-ray and tomosynthesis data to calculate breast-density maps, volumetric density, and a BI-RADS density category as an adjunct to qualified physician interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2018-09-21
FDA-cleared K173574

DenSeeMammo

Statlife

Authorized purpose: Adjunctive estimation of the BI-RADS 5th Edition breast-density category from processed digital 2D mammograms to aid radiologists; not diagnostic.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2018-06-26
FDA-cleared K170540

DM-Density

Densitas, Inc.

DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2018-02-23
FDA-cleared K163623

Quantra

HOLOGIC, INC.

Authorized purpose: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.

Modality
Mammography/DBT
Anatomy
Breast; mammographic breast-density composition
Decision
2017-10-20
FDA-approved P160009

PowerLook® Tomo Detection Software

iCAD Inc

Concurrent computer-aided detection for radiologists interpreting compatible GE Senoclaire breast tomosynthesis examinations, with detected soft-tissue densities blended into the synthetic two-dimensional mammography image.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2017-03-24
FDA-cleared K153427

Volpara Imaging Software

Matakina Technology LTD

Authorized purpose: Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2016-01-07
FDA-cleared K142037

QUANTRA

HOLOGIC, INC.

Authorized purpose: Quantra version 2.1 calculates volumetric and area breast-density measures and density categories from supported digital mammography images as an adjunct, not a diagnostic result.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2014-10-10
FDA-cleared K082483

QUANTRA

HOLOGIC, INC.

Authorized purpose: Quantra version 1.1 calculates a volumetric breast-density ratio from supported Hologic full-field digital mammography images on the Cenova server as an adjunct, not a diagnostic result.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2008-09-12
FDA-approved P010034

SECOND LOOK ™

ICAD, INC.

Authorized purpose: The Second Look computer-aided detection system for mammography is intended to identify and mark regions of interest on standard mammographic views after the initial reading has been completed, bringing them to the radiologist's attention and helping minimize observational oversights by identifying areas that may warrant a second review.

Modality
Mammography/DBT
Anatomy
Breast / standard mammographic views
Decision
2002-01-31
FDA-approved P970058

M1000 IMAGECHECKER

Hologic, Inc.

Authorized purpose: The ImageChecker M1000 is a computer system intended to identify and mark regions of interest on routine screening mammograms after the initial reading has been completed, bringing them to the radiologist's attention and helping minimize observational oversights by identifying areas that may warrant a second review.

Modality
Mammography/DBT
Anatomy
Breast / routine screening mammograms
Decision
1998-06-26